Renal p38 MAP kinase activity in experimental diabetes

Laboratory Investigation

Volumn 87, Issue 6, 2007, Pages 548-558

  Komers, Radko ^a,b   Lindsley, Jessie N ^a   Oyama, Terry T ^a   Cohen, David M ^a,c   Anderson, Sharon ^a,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Diabetic nephropathy; Hyperglycemia; p38 mitogen activated protein kinase; Proteinuria; Signaling

Indexed keywords

HUMAN INSULIN; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN PHOSPHATASE 1; PROTEIN; SYNAPTOPHYSIN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME MECHANISM; ENZYMOLOGY; GLOMERULOSCLEROSIS; GLOMERULUS; IMMUNOREACTIVITY; INSULIN TREATMENT; KIDNEY CORTEX; KIDNEY DISTAL TUBULE; MACULA DENSA; MALE; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES;

ACTIVATING TRANSCRIPTION FACTOR 2; ALBUMINURIA; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; INSULIN; KIDNEY CORTEX; KIDNEY GLOMERULUS; KIDNEY TUBULES, DISTAL; MALE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TREATMENT OUTCOME;

EID: 34249017571     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700549     Document Type: Article

References (40)

1. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001;81:807-869.
2. Kang SW, Adler SG, Lapage J, et al. p38 MAPK and MAPK kinase 3/6 mRNA and activities are increased in early diabetic glomeruli. Kidney Int 2001;60:543-552.
3. Burt DJ, Gruden G, Thomas SM, et al. P38 mitogen-activated protein kinase mediates hexosamine-induced TGFbeta1 mRNA expression in human mesangial cells. Diabetologia 2003;46:531-537.
4. Force T, Bonventre JV. Growth factors and mitogen-activated protein kinases. Hypertension 1998;31:152-161.
5. Tian W, Zhang Z, Cohen DM. MAPK signaling and the kidney. Am J Physiol 2000;279:F593-F604.
6. Ushio-Fukai M, Alexander RW, Akers M, et al. p38 mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. J Biol Chem 1998;273:15022-15029.
7. Muller E, Burger-Kentischer A, Neuhofer W, et al. Possible involvement of heat shock protein 25 in the angiotensin II-induced glomerular mesangial cell contraction via p38 MAP kinase. J Cell Physiol 1999;181:462-469.
8. Ge B, Gram H, Di Padova F, et al. MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. Science 2002;295:1291-1294.
9. Keyse SM. Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr Opin Cell Biol 2000;12:186-192.
10. Franklin CC, Kraft AS. Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. J Biol Chem 1997;272:16917-16923.
11. Igarashi M, Wakasaki H, Takahara N, et al. Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J Clin Invest 1999;103:185-195.
12. Natarajan R, Scott S, Bai W, et al. Angiotensin II signaling in vascular smooth muscle cells under high glucose conditions. Hypertension 1999;33:378-384.
13. Kang MJ, Wu X, Ly H, et al. Effect of glucose on stress-activated protein kinase activity in mesangial cells and diabetic glomeruli. Kidney Int 1999;55:2203-2214.
14. Zhang SL, Tang SS, Chen X, et al. High levels of glucose stimulate angiotensinogen gene expression via the P38 mitogen-activated protein kinase pathway in rat kidney proximal tubular cells. Endocrinology 2000;141:4637-4646.
15. Dai T, Natarajan R, Nast CC, et al. Glucose and diabetes: effects on podocyte and glomerular p38MAPK, heat shock protein 25, and actin cytoskeleton. Kidney Int 2006;69:806-814.
16. Susztak K, Raff AC, Schiffer M, et al. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006;55:225-233.
17. Adhikary L, Chow F, Nikolic-Paterson DJ, et al. Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy. Diabetologia 2004;47:1210-1222.
18. Sakai N, Wada T, Furuichi K, et al. Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy. Am J Kidney Dis 2005;45:54-65.
19. Komers R, Lindsley JN, Oyama TT, et al. Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 2001;107:889-898.
20. Widmann C, Gibson S, Jarpe MB, et al. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 1999;79:143-180.
21. Wilmer WA, Dixon CL, Hebert C. Chronic exposure of human mesangial cells to high glucose environments activates the p38 MAPK pathway. Kidney Int 2001;60:858-871.
22. Kang SW, Natarajan R, Shahed A, et al. Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen alpha5(IV) in experimental diabetic nephropathy and in glucose-stimulated podocytes. J Am Soc Nephrol 2003;14:3178-3187.
23. Hsieh TJ, Fustier P, Zhang SL, et al. High glucose stimulates angiotensinogen gene expression and cell hypertrophy via activation of the hexosamine biosynthesis pathway in rat kidney proximal tubular cells. Endocrinology 2003;144:4338-4349.
24. Liu BF, Miyata S, Hirota Y, et al. Methylglyoxal induces apoptosis through activation of p38 mitogen-activated protein kinase in rat mesangial cells. Kidney Int 2003;63:947-957.
25. Li JH, Huang XR, Zhu HJ, et al. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J 2004;18:176-178.
26. Tanno M, Bassi R, Gorog DA, et al. Diverse mechanisms of myocardial p38 mitogen-activated protein kinase activation: evidence for MKK-independent activation by a TAB1-associated mechanism contributing to injury during myocardial ischemia. Circ Res 2003;93:254-261.
27. Li J, Miller EJ, Ninomiya-Tsuji J, et al. AMP-activated protein kinase activates p38 mitogen-activated protein kinase by increasing recruitment of p38 MAPK to TAB1 in the ischemic heart. Circ Res 2005;97:872-879.
28. Begum N, Ragolia L. High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation. Am J Physiol 2000;278:C81-C91.
29. Igarashi M, Yamaguchi H, Hirata A, et al. Insulin activates p38 mitogen-activated protein (MAP) kinase via a MAP kinase kinase (MKK) 3/MKK 6 pathway in vascular smooth muscle cells. Eur J Clin Invest 2000;30:668-677.
30. Somwar R, Perreault M, Kapur S, et al. Activation of p38 mitogen-activated protein kinase alpha and beta by insulin and contraction in rat skeletal muscle: potential role in the stimulation of glucose transport. Diabetes 2000;49:1794-1800.
31. Sweeney G, Somwar R, Ramlal T, et al. An inhibitor of p38 mitogen-activated protein kinase prevents insulin-stimulated glucose transport but not glucose transporter translocation in 3T3-L1 adipocytes and L6 myotubes. J Biol Chem 1999;274:10071-10078.
32. Keeton AB, Amsler MO, Venable DY, et al. Insulin signal transduction pathways and insulin-induced gene expression. J Biol Chem 2002;277:48565-48573.
33. Cheng H-F, Wang J-L, Zhang M-Z, et al. Role of p38 in the regulation of renal cortical cyclooxygenase-2 expression by extracellular chloride. J Clin Invest 2000;106:681-688.
34. Wang J-L, Cheng H-F, Shappell S, et al. Cyclooxygenase-2 (COX-2) inhibition decreases proteinuria in a hypertensive diabetic model. J Amer Soc Nephrol 1999;10:A3505 (Abstract).
35. Cheng HF, Wang CJ, Moeckel GW, et al. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 2002;62:929-939.
36. Martineau LC, McVeigh LI, Jasmin BJ, et al. p38 MAP kinase mediates mechanically induced COX-2 and PG EP4 receptor expression in podocytes: implications for the actin cytoskeleton. Am J Physiol Renal Physiol 2004;286:F693-F701.
37. Hsieh TJ, Zhang SL, Filep JG, et al. High glucose stimulates angiotensinogen gene expression via reactive oxygen species generation in rat kidney proximal tubular cells. Endocrinology 2002;143:2975-2985.
38. de Borst MH, Navis G, de Boer RA, et al. Specific MAP-kinase blockade protects against renal damage in homozygous TGR(mRen2)27 rats. Lab Invest 2003;83:1761-1770.
39. Prakash J, Sandovici M, Saluja V, et al. Intracellular delivery of the p38 mitogen-activated protein kinase Inhibitor SB202190 [4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis. J Pharmacol Exp Ther 2006;319:8-19.
40. Westermann D, Rutschow S, Van Linthout S, et al. Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia 2006;49:2507-2513.